Paper Details

  1. Home
  2. Paper Details

Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.

Author: BailenJames, BassJoel, BelkoffLaurence, ChuFranklin, CossChristopher C, DaltonJames T, GamblaMichael, GaylisFranklin, GetzenbergRobert H, GittelmanMarc M, GivenRobert, HancockMichael L, KeaneThomas, SmithJordan, SteinerMitchell S, TutroneRonald, YuEvan Y

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Leuprolide reduced total testosterone more effectively than GTx-758, but GTx-758 lowered free testosterone and prostate-specific antigen more effectively. While GTx-758 reduced estrogen deficiency side effects, it had a higher incidence of venous thromboembolic events.
Paper Details　
Original Abstract of the Article :
BACKGROUND: A need remains for new therapeutic approaches for men with advanced prostate cancer, particularly earlier in the disease course. OBJECTIVE: To assess the ability of an oral selective estrogen receptor α agonist (GTx-758) to lower testosterone concentrations compared with leuprolide whil...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2014.06.011

データ提供：米国国立医学図書館（NLM）

GTx-758: A New Oasis in the Desert of Prostate Cancer Treatment?

In the field of [prostate cancer treatment], the search for [effective and tolerable therapies] continues. This study investigates the potential of [GTx-758], a [selective estrogen receptor α agonist], in lowering [testosterone levels] while minimizing the [side effects of androgen deprivation therapy] in men with [advanced prostate cancer]. The authors, like experienced desert guides, carefully navigate the complexities of this disease, seeking to find a treatment that balances efficacy with patient well-being.

GTx-758: A Potential Shortcut Through the Desert?

The study reveals that GTx-758 [effectively reduced testosterone levels] but with [fewer side effects] compared to [leuprolide]. While leuprolide was more effective in lowering total testosterone, GTx-758 showed a greater reduction in free testosterone and PSA levels, indicating potential for improved clinical outcomes. This suggests that GTx-758 might offer a more manageable path through the desert of prostate cancer treatment.

Managing the Side Effects: A Balance of Power in Prostate Cancer Therapy

The research emphasizes the importance of [minimizing side effects] in prostate cancer treatment. By finding a balance between [therapeutic efficacy and patient quality of life], we can navigate the desert of this disease in a way that is both effective and compassionate. Just as a camel chooses its path carefully to conserve its energy, clinicians must consider the potential side effects of treatment, ensuring that patients can endure the journey to recovery.

Dr. Camel's Conclusion

This study provides encouraging evidence for the potential of GTx-758 as a novel treatment for advanced prostate cancer. The drug’s ability to effectively lower testosterone levels with fewer side effects offers a promising alternative to existing therapies. Further research is needed to confirm these findings and explore the long-term implications of this treatment approach. Let us continue to explore the desert of prostate cancer, seeking new oases of hope and well-being for those affected by this disease.

Date :
  1. Date Completed 2015-12-17
  2. Date Revised 2015-03-12
Further Info :

Pubmed ID

24968970

DOI: Digital Object Identifier

10.1016/j.eururo.2014.06.011

Related Literature

Article Analysis
・Side Effects of estrogen
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.